These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 497409)

  • 1. [Detection of development of resistance in the short-term test (author's transl].
    Volm M; Maass E
    Blut; 1979 Oct; 39(4):289-92. PubMed ID: 497409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo and in vitro detection of induced resistance to daunorubicin in murine leukemia L 1210.
    Volm M; Maas E; Mattern J
    Arzneimittelforschung; 1981; 31(2):300-2. PubMed ID: 7194645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of induced resistance to cytosine-arabinoside with a short-term test.
    Volm M; Maas E; Mattern J
    Eur J Cancer (1965); 1980 May; 16(5):733-6. PubMed ID: 7389798
    [No Abstract]   [Full Text] [Related]  

  • 4. [Correlation between the effects of cytostatic agents on leukemia L 1210 in vivo and in the short term test in vitro (author's transl)].
    Volm M; Hummel H; Mattern J
    Blut; 1977 Jul; 35(1):65-74. PubMed ID: 890146
    [No Abstract]   [Full Text] [Related]  

  • 5. A computer model for tumor growth and chemotherapy, and its application to L1210 leukemia treated with cytosine arabinoside (NSC-63878).
    Shackney SE
    Cancer Chemother Rep; 1970 Dec; 54(6):399-429. PubMed ID: 5527022
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of different doses of methotrexate (NSC-740), cytosine arabinoside (NSC-63878), and cyclophosphamide (NSC-26271) on drug resistance in mice with L1210 leukemia.
    Schmid FA; Hutchison DJ
    Cancer Chemother Rep; 1972 Aug; 56(4):473-81. PubMed ID: 5081590
    [No Abstract]   [Full Text] [Related]  

  • 7. Chronochemotherapy of L1210 leukemic mice with cytosine arabinoside or cyclophosphamide.
    Rose WC; Trader MW; Laster WR; Schabel FM
    Cancer Treat Rep; 1978 Sep; 62(9):1337-49. PubMed ID: 688277
    [No Abstract]   [Full Text] [Related]  

  • 8. Reduction in the frequency of mutation to resistance to cytarabine in L1210 murine leukemic cells by treatment with quinacrine hydrochloride.
    Bach MK
    Cancer Res; 1969 Oct; 29(10):1881-5. PubMed ID: 5823955
    [No Abstract]   [Full Text] [Related]  

  • 9. Experimental and clinical studies on nucleoside analogs as antitumor agents.
    Burchenal JH; Currie VE; Dowling MD; Fox JJ; Krakoff IH
    Ann N Y Acad Sci; 1975 Aug; 255():202-12. PubMed ID: 1059355
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacokinetics and cellular determinants of response to 1-beta-arabinofuranosylcytosine (ara-C).
    Riva CM; Rustum YM; Preisler HD
    Semin Oncol; 1985 Jun; 12(2 Suppl 3):1-8. PubMed ID: 3859925
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of 3-deazauridine on the metabolism, toxicity, and antitumor activity of azacitidine in mice bearing L1210 leukemia sensitive and resistant to cytarabine.
    Li ZR; Campbell J; Rustum YM
    Cancer Treat Rep; 1983 Jun; 67(6):547-54. PubMed ID: 6190558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Studies of the L1210 antileukemic activity of O-2,2'-cyclocytidine, monoacetate (anhydro-ara-C; NSC-129220)--comparison with cytosine arabinoside (NSC-63878) with respect to treatment schedule dependency.
    Venditti JM; Baratta MC; Greenberg NH; Abbott BJ; Kline I
    Cancer Chemother Rep; 1972 Aug; 56(4):483-92. PubMed ID: 5081591
    [No Abstract]   [Full Text] [Related]  

  • 13. [Cytostatic action of 2-nitronaph-thofurans on L1210 murine leukemia cells in semi-solid médium (author's transl)].
    Gruest J; Montagnier L; Buisson JP; Royer R
    Bull Cancer; 1981; 68(4):328-31. PubMed ID: 7317658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Collateral sensitivity of resistant lines of mouse leukemias L1210 and L5178Y.
    Schmid FA; Hutchison DJ
    Cancer Res; 1972 Apr; 32(4):808-12. PubMed ID: 5014791
    [No Abstract]   [Full Text] [Related]  

  • 15. Letter: Proposed new derivative of cytosine arabinoside (NSC-63878) to circumvent resistance.
    Cysyk RL
    Cancer Chemother Rep; 1974; 58(3):298-9. PubMed ID: 4842665
    [No Abstract]   [Full Text] [Related]  

  • 16. Separate and sequential chemotherapy of mouse leukemia L1210 with 1-beta-D-arabinofuranosylcytosine hydrochloride and 1,3-bis(2-chloroethyl)-1-nitrosourea.
    Tyrer DD; Kline I; Venditti JM; Goldin A
    Cancer Res; 1967 May; 27(5):873-9. PubMed ID: 6025252
    [No Abstract]   [Full Text] [Related]  

  • 17. Nucleoside conjugates. 10. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine 5'-diphosphate-1,2-dipalmitins.
    Hong CI; An SH; Schliselfeld L; Buchheit DJ; Nechaev A; Kirisits AJ; West CR
    J Med Chem; 1988 Sep; 31(9):1793-8. PubMed ID: 3411602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancement of the cancer chemotherapeutic effect of cytosine arabinoside entrapped in liposomes on mouse leukemia L-1210.
    Kobayashi T; Tsukagoshi S; Sakurai Y
    Gan; 1975 Dec; 66(6):719-20. PubMed ID: 1225724
    [No Abstract]   [Full Text] [Related]  

  • 19. Chemotherapy of leukemia L1210 in mice with 1-beta-d-arabinofuranosylcytosine hydrochloride. I. Influence of treatment schedules.
    Kline I; Venditti JM; Tyrer DD; Goldin A
    Cancer Res; 1966 May; 26(5):853-9. PubMed ID: 5936445
    [No Abstract]   [Full Text] [Related]  

  • 20. Sequential chemotherapy with cyclophosphamide (NSC-26271) and cytosine arabinoside (NSC-63878) in mice with advanced leukemia L1210.
    Hoffman GS; Kline I; Gang M; Tyrer DD; Goldin A; Mantel N; Venditti JM
    Cancer Chemother Rep; 1969 Oct; 53(5):265-71. PubMed ID: 5377613
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.